Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy (Beta3‐LVH)

AIMS: Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3‐LVH trial will test the hypothesis that the β(3) adrenergi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESC Heart Fail
Main Authors: Pouleur, Anne‐Catherine, Anker, Stefan, Brito, Dulce, Brosteanu, Oana, Hasenclever, Dirk, Casadei, Barbara, Edelmann, Frank, Filippatos, Gerasimos, Gruson, Damien, Ikonomidis, Ignatios, Lhommel, Renaud, Mahmod, Masliza, Neubauer, Stefan, Persu, Alexandre, Gerber, Bernhard L., Piechnik, Stefan, Pieske, Burkert, Pieske‐Kraigher, Elisabeth, Pinto, Fausto, Ponikowski, Piotr, Senni, Michele, Trochu, Jean‐Noël, Van Overstraeten, Nancy, Wachter, Rolf, Balligand, Jean‐Luc
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6165933/
https://ncbi.nlm.nih.gov/pubmed/29932311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados